Corient Private Wealth’s Twist Bioscience TWST Stock Holding History

Corient Private Wealth’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+21,636	New	+$1.41M	﹤0.01%	1332

Other funds holding TWST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Corient Private Wealth's TWST Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Twist Bioscience (TWST) in Q2 2026: 21,636 shares worth $2.23M. The stake represents ﹤0.01% of the portfolio and ranks #1332 among its holdings.

335 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

Corient Private Wealth held 21,636 shares of Twist Bioscience worth $2.23M as of Q2 2026.
Twist Bioscience was a new Corient Private Wealth position in Q2 2026.
Twist Bioscience made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1332 holding.
335 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.